{
    "links": "https://www.ycombinator.com/companies/hepatx",
    "name": "Hepatx",
    "headline": "Replacing organ transplant with an infusion",
    "batch": "S18",
    "description": "Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.",
    "activity_status": "Active",
    "website": "http://www.hepatx.com",
    "founded_date": 2015.0,
    "team_size": 4.0,
    "location": "Palo Alto",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:biotech; location:san-francisco-bay-area",
    "founders": [],
    "status": true,
    "generated_description": "Hepatx is a pioneering biotech company founded in 2015, operating out of Palo Alto, California. Part of Y Combinator\u2019s Batch S18, Hepatx is on a bold mission: to replace organ transplants for liver diseases with a revolutionary infusion therapy. It\u2019s a game-changer, considering that over 30 million Americans suffer from liver disease, with 200,000 annually reaching end-stage liver failure\u2014a condition that traditionally requires a transplant, yet only 1 in 33 patients actually receive the organ they need.\n\nThe company is focused on developing off-the-shelf cell therapies, using advanced regenerative medicine technologies and stem cells to create effective treatments for patients in dire need. Their approach not only aims to revolutionize the treatment of liver disease but also to alleviate the immense pressure on the overwhelmed transplant system that sees thousands of patients waiting for care.\n\nThe Hepatx team, currently consisting of four dedicated employees, boasts a robust background in medical science and entrepreneurial innovation. With a scalable manufacturing process, they are positioned to make liver regeneration clinically viable, all while ensuring economic practicality. They\u2019re not just looking to improve liver care; they\u2019re committed to redefining it.\n\nRecognizing the vast potential for impact, Hepatx is also keen on educating the public about their therapies and attracting investment to expand their reach. Their dedication has not gone unnoticed\u2014they were awarded the 2022 Impact Company of the Year by DotCom Magazine.\n\nIn a world where chronic liver conditions affect millions, Hepatx is striving to usher in a new era of healing, promising to change lives with their innovative solutions. The goal is clear: to free patients from the burdens of chronic disease through better regenerative options. You can dive deeper into their work on their website [hepatx.com](http://www.hepatx.com).\n\nIn short, Hepatx isn\u2019t just another biotech company; it\u2019s a vital part of a much-needed revolution in healthcare, aiming to harness the power of regenerative medicine to save lives.",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/b92263912d121cd5bd33746820ecfaf20c9bdbec.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAKBB576US%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191417Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJHMEUCIFRjVxB%2FHxIJHUHkMazoRi02jYmaJVJGr3K7C9j9jiflAiEA6iszI4%2Fpn8hDzk7aMP6LlnqynbPgCG20CpdZqslTFdsq7gMI3P%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAAGgwwMDYyMDE4MTEwNzIiDNVC6v4lNMvTlUOjTyrCA7R4NjcD6pWk9Gjux5NdrMhwU67pNo%2F0JVDzkHcTjBsajnWXpXoyD3m%2FssX0rwYmnUDJB9VTgD%2FW2M8cWxeD93WFxLjs25juzzGj1%2BC1Ky9E0oNPwn5jGw%2BjokWylkxcouU18mjUtP8juH4uF9Xfmm%2FMAgvOPsNSAaYBQ%2BdA5Vwom66MCzynAPEJs6Nqxd5FqtgiiWFRhT5L9g%2FvfLTKqpdIg0XPF6s95lLCtwWDHST72Bn9JVH2zZmqjTgO2sao7Rg4M%2BPIRazg8JhbPoWk6xsB2yfG1f%2Bs8AFVxihyUnQj6TUnhrhezs7WYsaTfaaAoTIzhEsLwJDqBQDSptmSlUj%2BQ3KWwrXpJIm0b1uOmaylnrEpn5obECdRc%2FzdEfNt6DNEE5cbUhQo8Gjfd6MWfyV7JHtX7DwsLMssQPKNZ6qWJq2gP1fVHFkz5K0F%2F73p54AKB5gCkyOeRPJHmAzYMdfZpMF%2B8hE4eZU6k7m1EqPLEW2F9HVvcqPFp8T%2BZgbbDLBVWICSdX%2FfJ%2BniwyC72aHLaqjCxHLvJ6WyAawaepaDD9csEvz4DYD9lpHx9hJXqrFDyrT1vAaaBwuoXgulZ6gNmjCmiuO9BjqlATnnhPFnQUT7QmhXwrAFbGCqdgkRFIVCdDrNmasZJtz86frmIpB%2BlwZjavL0FMq46mN9RKFTuRNdMnOtOh1adMI%2BkC%2F%2Bs3m8pwR56JxErG%2B8nIBe7efeu5WiUZbGCsp85oXBCGY%2FoP1uWrJo843L0LVdmjtyXaDurxXSgzfeZo2RDONME7LNkPzuGzA19XefIc9OvA1QFcZr3VIdZe%2BLywfFgDpgwA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=f1d03941a27a75197c81f76798e69351f949fec4acefefab231a8e74e1ba6886",
    "social_links": [
        "https://www.linkedin.com/company/hepatx-corporation/",
        "https://twitter.com/hepatx?lang=en",
        "https://www.crunchbase.com/organization/hepatx"
    ],
    "logo_path": "data/logos\\Hepatx_logo.png"
}